Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
At what pace is the renal insufficiency market growing, and what is its estimated value?
The renal insufficiency market size has grown rapidly in recent years. It will grow from $10.87 billion in 2024 to $12.14 billion in 2025 at a compound annual growth rate (CAGR) of 11.7%. The growth in the historic period can be attributed to increasing cases of high blood pressure and diabetes, increasing prevalence of chronic kidney disease (CKD), rising prevalence of obstructions in the urinary tract, aging population, and increasing awareness and education regarding kidney health.
The renal insufficiency market size is expected to see rapid growth in the next few years. It will grow to $18.68 billion in 2029 at a compound annual growth rate (CAGR) of 11.4%. The growth in the forecast period can be attributed to increasing prevalence of acute kidney injuries (AKI), increasing adoption of home-based treatment options, surge in healthcare expenditure, and investments in research and development. Major trends in the forecast period include advancements in medical technology, advancements in technology and treatment options, integration of personalized medicine, advancements in dialysis technology, and development of new and innovative medications.
Get Your Free Sample of The Global Renal Insufficiency Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21271&type=smp
What are the top drivers to the rising demand in the renal insufficiency market?
The increasing number of high blood pressure and diabetes cases is expected to propel the growth of the renal insufficiency market going forward. Blood pressure and diabetes are attributed to factors such as poor diet, lack of physical activity, obesity, genetic predisposition, and an aging population. High blood pressure damages kidney blood vessels by causing scarring and reduced filtration, while diabetes leads to thickened and overworked kidney vessels due to high blood sugar, with both conditions accelerating kidney damage and leading to renal insufficiency. For instance, in May 2024, according to the National Health Service, a UK-based government agency, in December 2023, the number of high blood pressure diagnoses in the South East increased by 71,120 patients, marking a 5.4% rise compared to December 2022. Further, in April 2023, according to the British Diabetic Association, a UK-based charity organization, 4.3 million people are living with a diabetes diagnosis in the UK. Therefore, the increasing number of high blood pressure and diabetes cases is driving the growth of the renal insufficiency market.
How is the renal insufficiency market segmented?
The renal insufficiency market covered in this report is segmented –
1) By Treatment Type: Medications, Dialysis, Kidney Transplantation, Other Treatment Types
2) By Disease Stage: Chronic Kidney Disease (CKD) Stages, End-Stage Renal Disease (ESRD)
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
4) By End-User: Dialysis Centers, Hospital And Clinics, Research And Academic Institutes
Subsegments:
1) By Medications: Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Diuretics, Erythropoiesis-Stimulating Agents (ESAs), Phosphate Binders, Sodium Bicarbonate
2) By Dialysis: Hemodialysis, Peritoneal Dialysis, Home Dialysis, Continuous Renal Replacement Therapy (CRRT)
3) By Kidney Transplantation: Living Donor Kidney Transplant, Deceased Donor Kidney Transplant, Kidney Transplant Immunosuppressive Therapy
4) By Other Treatment Types: Lifestyle And Dietary Modifications, Stem Cell Therapy, Gene Therapy
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/renal-insufficiency-global-market-report
Who are the top competitors in the renal insufficiency market?
Major companies operating in the renal insufficiency market are Kaiser Permanente, Johnson & Johnson, Roche Holding AG, Sanofi S.A., Abbott Laboratories, Medtronic plc, Amgen Inc., Asahi Kasei Medical Co. Ltd., Fujifilm Holdings Corporation, Fresenius Medical Care, Toray Industries Inc., Baxter International Inc., Boehringer Ingelheim, DaVita Inc., Eisai Co. Ltd., Nipro Corporation, Biocon Limited, HemoCue AB, Rockwell Medical, Mitsubishi Tanabe Pharma Corporation, Sorin Group.
What significant trends should we anticipate in the renal insufficiency market over the forecast period?
Major companies operating in the renal insufficiency market are developing glucagon-like peptide-1 receptor agonists (GLP-1 RAs) to address renal and cardiovascular complications in patients with diabetes and chronic kidney disease (CKD). GLP-1 RAs improve glucose control, reduce inflammation, and lower oxidative stress in the kidneys, thereby slowing the progression of renal insufficiency. For instance, in January 2025, Novo Nordisk, a Denmark-based pharmaceutical company, received Food and Drug Administration (FDA) approval for its Ozempic (semaglutide) to reduce the risk of kidney disease worsening, kidney failure, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease (CKD). This approval highlights the growing emphasis on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as a dual approach to managing both diabetes and renal insufficiency, addressing critical unmet needs in patients with progressive CKD.
Which regional trends are influencing the renal insufficiency market, and which area dominates the industry?
North America was the largest region in the renal insufficiency market in 2024. The regions covered in the renal insufficiency market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Renal Insufficiency Market Report 2025 Offer?
The renal insufficiency market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Renal insufficiency refers to the reduced ability of the kidneys to filter waste products and maintain fluid and electrolyte balance in the body. It can result from chronic conditions such as diabetes, hypertension, or acute kidney injury, leading to the accumulation of toxins in the blood. If left untreated, renal insufficiency may progress to chronic kidney disease (CKD) or kidney failure, requiring dialysis or transplantation.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21271
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
